Advanced RCC has seen many treatment advances in the last several years, with the introduction of many novel therapies. Recent evidence from the KEYNOTE 426 and CheckMate 214 studies has mandated a rearrangement of treatment algorithms for advanced clear-cell RCC. We now await both clinical experience and prospective clinical trials to help inform the optimal sequence of therapy with these newer therapies, VEGF-targeted therapies and other evidence-based options. Ongoing participation in research and clinical trials to further our knowledge in this field continues to be an essential priority for healthcare professionals with an interest in advanced RCC. Therapy should be individualized based on patient profiles and disease characteristics, and each agent chosen should be optimized to obtain best results, with multidisciplinary care being paramount in achieving maximal benefit for patients.
No takes yet. Share an insight, caveat, or question.
Hotte et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: